权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genetic hearing screening and diagnosis facilitated by using a combined low-cost

通过使用低成本的组合来促进遗传听力筛查和诊断

基本信息

批准号：
8137687
负责人：
XI LIN
金额：
$ 53.66万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-25 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8137687
关键词：
Adopted Auditory Brainstem Responses Base Pairing Base Sequence Birth Businesses Canada Candidate Disease Gene Charge Chromosomes Clinical Clinical Protocols Communication impairment Comparative Study Complementary DNA Computer software Country Coupling Custom Cytomegalovirus DNA Data Detection Developed Countries Developing Countries Development Devices Diagnosis Diagnostic Diagnostic tests Disease Disease Management Eligibility Determination Environment Epidemiology Etiology Europe Exons Future Gene Mutation Generations Genes Genetic Genetic Markers Genetic Materials Genetic Screening Genetic screening method Genome Genomics Genotype Glass Goals Grant Hearing Hearing Impaired Persons Housing Human Individual Infection Information Technology Inherited Intervention Japan Laws Length Letters Location Manuals Marketing Measurement Medical center Messenger RNA Methods Mitochondria Mutation Mutation Detection NIH Program Announcements Nature Newborn Infant Noise Oligonucleotides Outcome Patients Persons Phase Phased Innovation Awards Physiology Predisposition Prevalence Price Printing Procedures Production Protocols documentation Publishing Qualifying Reporting Research Research Infrastructure Risk Running Sample Size Sampling Screening procedure Sensitivity and Specificity Services Slide Specialist Specificity Structure System Techniques Technology Testing Time Translating United States Validation age related base cDNA Probes clinical Diagnosis clinical application clinical phenotype clinical practice commercialization cost deafness density design early onset flexibility gene interaction hearing impairment hearing screening improved mutant new technology next generation novel novel strategies operation otoacoustic emission postnatal programs public health relevance statistics tool treatment strategy

项目摘要

DESCRIPTION (provided by applicant): Universal newborn hearing screening is a widely-adopted clinical practice and mandated by law in the United States. Current physiology-based hearing screening protocol generates high false positive rate and is unable to detect early-onset hearing loss and provide a diagnosis that defines underlying etiology. Studies have indicated that the primary diagnostic concern in congenital hearing loss is genetic mutations in deafness genes and infections with cytomegalovirus. Recent advances in massively-parallel sequencing technologies have made it possible to routinely analyze targeted sets of human genes totaling millions of base pairs. However, the new technology has not been validated with deafness genes. More importantly, the high cost associated with capturing targeted deafness genes makes it unlikely that these technological advances will be translated into a widely-adopted clinical tool. The R21 phase of the project will test and validate the core technology for a low-cost approach to efficiently capture exons of most common deafness genes and its suitability for coupling with various types of downstream sequencing applications by massively parallel sequencers for the detection of genetic mutations. In the R33 phase we will expand the capturing coverage of our custom genechips to include all confirmed deafness genes and deafness gene candidates. The overall goal of the project is to provide a cost-competitive and mature implementation protocol for a DNA-based approach for hearing screening that will significantly enhance the current universal newborn hearing screening program. PUBLIC HEALTH RELEVANCE: Recent advances in massively-parallel sequencing technologies have made it possible to routinely analyze targeted sets of human genes totaling millions of base pairs. However, the new technology has not been validated with deafness genes and the high cost associated with capturing targeted deafness genes makes it unlikely that these technological advances will be translated into a widely-adopted clinical tool. This project will test and validate the core technology for a low-cost approach to efficiently capture exons of all confirmed deafness genes and deafness gene candidates. The overall goal of the project is to provide a DNA-based hearing screening method that will significantly enhance the current universal newborn hearing screening program.

描述（由申请人提供）：普遍新生儿听力筛查是一项广泛采用的临床实践，并在美国法律强制执行。目前基于生理学的听力筛查方案产生高假阳性率，无法发现早发性听力损失并提供明确潜在病因的诊断。研究表明先天性听力损失的主要诊断是耳聋基因突变和巨细胞病毒感染。大规模平行测序技术的最新进展使得常规分析总计数百万碱基对的人类基因目标组成为可能。然而，这项新技术还没有在耳聋基因上得到验证。更重要的是，捕获目标耳聋基因的高成本使得这些技术进步不太可能转化为广泛采用的临床工具。该项目的R21阶段将测试和验证一种低成本方法的核心技术，以有效捕获大多数常见耳聋基因的外显子，并通过大规模并行测序仪与各种类型的下游测序应用相结合，以检测基因突变。在R33阶段，我们将扩大我们的定制基因芯片的捕获范围，包括所有确认的耳聋基因和耳聋基因候选。该项目的总体目标是为基于dna的听力筛查方法提供一个具有成本竞争力和成熟的实施方案，这将大大增强当前普遍的新生儿听力筛查计划。